Atopaxar and its effects on markers of platelet activation and inflammation: Results from the LANCELOT CAD program

Journal of Thrombosis and Thrombolysis

Volumn 34, Issue 1, 2012, Pages 36-43

  O'Donoghue, Michelle L ^a   Bhatt, Deepak L ^a   Flather, Marcus D ^b   Goto, Shinya ^c   Angiolillo, Dominick J ^d   Goodman, Shaun G ^e   Zeymer, Uwe ^f   Aylward, Philip E ^g   Montalescot, Gilles ^h   Ziecina, Rafal ⁱ   Kobayashi, Hiroyuki ^c   Ren, Fang ^a   Wiviott, Stephen D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c TOKAI UNIVERSITY   (Japan)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

^g FLINDERS UNIVERSITY   (Australia)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ EISAI CO LTD   (Japan)

Author keywords

Atopaxar; Biomarkers; Coronary artery disease; PAR 1 receptor antagonist

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATOPAXAR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; PLACEBO; PLACENTAL GROWTH FACTOR; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ANTAGONIST;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL MODEL; THROMBOCYTE ACTIVATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CD40 LIGAND; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMINES; INFLAMMATION; INTERLEUKIN-18; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PLATELET ACTIVATION; PYRIDINES; RECEPTOR, PAR-1; TIME FACTORS;

EID: 84862764516     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0750-6     Document Type: Article

References (12)

1. DJ Angiolillo D Capodanno S Goto 2010 Platelet thrombin receptor antagonism and atherothrombosis Eur Heart J 31 1 17 28 10.1093/eurheartj/ehp504 19948715 10.1093/eurheartj/ehp504 1:CAS:528:DC%2BC3cXhtFOmsQ%3D%3D
2. ML O'Donoghue DL Bhatt SD Wiviott SG Goodman DJ Fitzgerald DJ Angiolillo S Goto G Montalescot U Zeymer PE Aylward V Guetta D Dudek R Ziecina CF Contant MD Flather 2011 Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial Circulation 123 17 1843 1853 10.1161/CIRCULATIONAHA.110.000786 21502577 10.1161/CIRCULATIONAHA.110.000786
3. SD Wiviott MD Flather ML O'Donoghue S Goto DJ Fitzgerald F Cura P Aylward V Guetta D Dudek CF Contant DJ Angiolillo DL Bhatt 2011 Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial Circulation 123 17 1854 1863 10.1161/CIRCULATIONAHA.110.001404 21502571 10.1161/CIRCULATIONAHA.110.001404 1:CAS:528:DC%2BC3MXlsVynsbw%3D
4. VL Serebruany M Kogushi D Dastros-Pitei M Flather DL Bhatt 2009 The in vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease Thromb Haemost 102 1 111 119 10.1160/TH08-12-0805 19572075 1:CAS:528:DC%2BD1MXptlemurg%3D
5. S Goto H Ogawa M Takeuchi MD Flather DL Bhatt 2010 Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Eur Heart J 31 21 2601 2613 10.1093/eurheartj/ehq320 20805115 10.1093/eurheartj/ehq320 1:CAS:528: DC%2BC3cXhsVSlt7nP
6. Kogushi M, Yokohama H, Kitamura S, Hishinuma I (2007) Effects of E5555, a protease activated receptor-1 antagonist, on the inflammatory markers in vitro. J Thromb Haemost 5:P-M-059 (abstract)
7. M Hagihara A Higuchi N Tamura Y Ueda K Hirabayashi Y Ikeda S Kato S Sakamoto T Hotta S Handa S Goto 2004 Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro J Immunol 172 9 5297 5303 15100268 1:CAS:528:DC%2BD2cXjt1Cksb0%3D
8. SR Coughlin E Camerer 2003 PARticipation in inflammation J Clin Investig 111 1 25 27 10.1172/JCI17564 12511583 1:CAS:528:DC%2BD3sXhvVansA%3D%3D
9. G Montalescot G Sideris C Meuleman C Bal-dit-Sollier N Lellouche PG Steg M Slama O Milleron JP Collet P Henry F Beygui L Drouet 2006 A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial J Am Coll Cardiol 48 5 931 938 16949482 10.1016/j.jacc.2006.04. 090 1:CAS:528:DC%2BD28XpsVWmtbo%3D
10. S Husted RF Storey RA Harrington H Emanuelsson CP Cannon 2010 Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel Clin Cardiol 33 4 206 212 10.1002/clc.20732 20394040 10.1002/clc.20732
11. P Tricoci Z Huang C Held DJ Moliterno PW Armstrong F Van de Werf HD White PE Aylward L Wallentin E Chen Y Lokhnygina J Pei S Leonardi TL Rorick AM Kilian LH Jennings G Ambrosio C Bode A Cequier JH Cornel R Diaz A Erkan K Huber MP Hudson L Jiang JW Jukema BS Lewis AM Lincoff G Montalescot JC Nicolau H Ogawa M Pfisterer JC Prieto W Ruzyllo PR Sinnaeve RF Storey M Valgimigli DJ Whellan P Widimsky J Strony RA Harrington KW Mahaffey 2011 Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 10.1056/NEJMoa1109719 22077816
12. DA Morrow E Braunwald MP Bonaca SF Ameriso AJ Dalby MP Fish KA Fox LJ Lipka X Liu JC Nicolau AJ Ophuis E Paolasso BM Scirica J Spinar P Theroux SD Wiviott J Strony SA Murphy 2012 Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 15 1404 1413 10.1056/NEJMoa1200933 22443427 10.1056/NEJMoa1200933 1:CAS:528:DC%2BC38XlslOrsLk%3D